Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Common Equity (2018 - 2025)

Exagen (XGN) has disclosed Common Equity for 8 consecutive years, with $17.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 82.9% year-over-year to $17.4 million, compared with a TTM value of $17.4 million through Dec 2025, up 82.9%, and an annual FY2025 reading of $17.4 million, up 82.9% over the prior year.
  • Common Equity was $17.4 million for Q4 2025 at Exagen, down from $18.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $101.5 million in Q1 2021 and bottomed at $6.4 million in Q1 2025.
  • Average Common Equity over 5 years is $42.6 million, with a median of $29.7 million recorded in 2023.
  • The sharpest move saw Common Equity surged 104.17% in 2021, then crashed 67.97% in 2025.
  • Year by year, Common Equity stood at $84.9 million in 2021, then crashed by 50.01% to $42.5 million in 2022, then crashed by 46.55% to $22.7 million in 2023, then crashed by 57.96% to $9.5 million in 2024, then skyrocketed by 82.9% to $17.4 million in 2025.
  • Business Quant data shows Common Equity for XGN at $17.4 million in Q4 2025, $18.1 million in Q3 2025, and $21.0 million in Q2 2025.